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Globalisation of clinical trials and ethics of benefi t sharing
The Declaration of Helsinki1 holds that if medical 
research is done within a vulnerable group, this group 
should stand to benefi t from the knowledge, practices, 
or interventions resulting from the research. This 
principle, reaffi  rmed by all versions of the Declaration 
released in this millennium, represents the need for 
a direct link between obtaining scientifi c results and 
achieving health benefi ts in vulnerable groups.1 
Vulnerability is generally defi ned as having diminished 
autonomy and increased likelihood of incurring harm or 
exploitation. On the basis of t he rights to integrity and 
autonomy, vulnerable people should receive assistance 
to enable them to realise their potential. In medical 
research, vulnerability is often perceived in relation to 
individuals who are minor of age, institutionalised, or 
incapacitated on medical grounds. However, vulnerability 
goes beyond juridical, cognitive, and medical boundaries. 
For instance, the Belmont Report includes minorities and 
the economically disadvantaged in their classifi cation 
of vulnerable groups. In poor countries, vulnerability is 
often linked to poverty, social exclusion, and poor access 
to health care. This relation might drive populations 
towards participation in clinical trials as a way to secure 
access to free health care, which would be otherwise 
unavailable.
The ethical guidelines for medical research by the 
Council for International Organizations of Medical 
Sciences tackle the issue of research in socio-
economically vulnerable communities.2 In line with the 
Helsinki Declaration and the principles of solidarity and 
non-discrimination, the guidelines unequivocally state 
that any product developed in a research programme 
should be made available to the population involved 
in that research. If there are reasons to believe that 
these conditions will not take place, the guidelines 
deem it unethical and exploitative to do the research 
in that country. To share the burdens and benefi ts of 
research fairly, innovative drugs showing superiority 
over the standard of care should become accessible and 
aff ordable to prospective patients residing in the study 
countries within a reasonable time frame. 
The development of costly life-saving drugs 
against non-communicable diseases through trials 
done in middle-income countries (MICs) poses 
ethical challenges  that, to our knowledge, have not 
been investigated in depth. MICs are defi ned by the 
World Bank as having a yearly gross national income 
(GNI) per head greater than US$1045 and less than 
$12 746.3 Haematological malignancies might be a 
useful setting in which to monitor the benefi ts and 
ethical implications of clinical trials in MICs, since 
they are ubiquitous and drugs exist that either cure 
or permit long-term control in a substantial number 
of patients. The downside of these drugs, whether 
they are recombinant monoclonal antibodies or small 
molecules that target specifi c molecular pathways, is 
their high cost, which might be unsustainable in MICs. 
For Belmont Report see hhs.
gov/ohrp/humansubjects/
guidance/belmont.html
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Figure: Involvement of middle-income countries in clinical trials for 
haematologic malignancies
(A) Proportion of interventional, industry-sponsored clinical trials run in MICs for 
leukaemia, lymphoma, and multiple myeloma. (B) Clinical trial sites in MICs 
included in studies testing 12 new drugs against leukaemia, lymphoma, or 
multiple myeloma (n=73). Only MICs with more than ten study sites are shown. 
MICs with less than ten study sites include Albania, Algeria, Belarus, Bosnia 
Herzegovina, Dominican Republic, Ecuador, El Salvador, Georgia, Guatemala, 
Indonesia, Macedonia, Montenegro, Morocco, Panama, Tunisia, Venezuela, and 
Vietnam. MIC=middle-income country. HIC=high-income country.
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As an example, the cost of treating chronic myeloid 
leukemia with a fi rst generation small molecule drug 
exceeds $40 000 per patient per year in South Africa.4 
Such an expense is more than 130 times the yearly 
per head government expenditure rate on health 
care ($309 in 2012) and about six times the GNI per 
head ($7190 in 2013).3,5 In a high-income country like 
Italy, the yearly cost for the same condition would be 
13 times the yearly per head government expenditure 
rate on health care, and 1·1 times the GNI per head.3–5 
In MICs, accessibility to health care is further reduced 
because of high poverty, high out-of-pocket payments, 
and low health protection coverage. According to the 
International Labour Organization, of 58 MICs for which 
data are available, 39 have a medium-to-very-high level 
of vulnerability, with proportions of the population 
not covered by any legal health protection ranging 
from 30·8–88·4%.6 For most people in these countries, 
treating haematological malignancies with costly 
drugs might represent a catastrophic expense, pushing 
patients and families into extreme poverty.
Trials for haematological malignancies have followed 
a trend for globalisation that is characteristic of clinical 
research in the past years.7,8 Of all phase 3, interventional, 
industry-sponsored clinical trials with innovative 
drugs against leukaemia (1228 trials), lymphoma 
(1344 trials), or multiple myeloma (610 trials) that have 
been submitted to ClinicalTrials.gov (as of July 14, 2014), 
about 30% involved sites in MICs, including both low-
middle-income and upper-middle-income countries 
(fi gure). We defi ned MICs according to the World Bank 
classifi cation (2015 fi scal year), which might present 
minor diff erences to the classifi cation at the time the 
various studies were started. 
We analysed in greater detail the studies of 12 drugs 
recommended by international guidelines or which are 
under development (eight small molecules: bortezomib, 
carfi lzomib, dasatinib, ibrutinib, idelasilib, imatinib, 
lenalidomide, and nilotinib; and four monoclonal 
antibodies: brentuximab, obinu tuzumab, ofatumumab, 
and rituximab; fi gure). We identifi ed 73 inter national, 
industry-sponsored studies (four phase 1; 19 phase 2; 
50 phase 3) involving MICs in ClinicalTrials.gov. When 
considering all 9559 study sites, the proportion of sites 
in MICs was 18·0% (range 1·6–79·0). When restricting 
the analysis to sites located outside USA (n=8142), 
21·1% (2·1–79·0) were in MICs. The highest proportion 
of MIC sites in any trial (79·01%) was in a phase 3 trial, 
whereas the proportion of MIC sites in phase 1 and 2 
trials did not exceed 25·8% and 33·7%, respectively. 
Trials run in MICs targeted all age groups, including 
children, adolescents, and elderly people.
A peculiar issue occurs in phase 3 trials that compare 
costly, life-saving drugs close to patent expiration 
with a second-generation compound developed by 
the same patent holder. Such trials have been done 
in MICs even though the control drug had never been 
widely accessible, despite its common use for more 
than a decade in affl  uent countries. These trials might 
raise a substantial ethical issue, because neither the 
comparator nor the investigational compound have had 
or will have a reasonable chance of becoming accessible 
to all those in need in the study country. 
Overall, the drive for globalisation of clinical trials 
of costly drugs adds a further degree of complexity 
to the ethical concerns surrounding trials that might 
be delocalised for administrative convenience, as 
highlighted in the Belmont Report. Moving them, at 
least partly, to MICs could shorten the timelines of 
clinical development, thanks to a combination of lower 
research costs, availability of larger pools of potential 
participants, and less stringent oversight.9 
The shift in geographical boundaries of trials with 
costly drugs should prompt a quest for ethically 
acceptable solutions, rather than being perceived as 
an obstacle toward MIC involvement. An active role of 
MICs in research is benefi cial if a reasonable likelihood 
that their populations will benefi t from the research 
exists. Several strategies might be explored. First, 
scientifi c journals should publish a complete list of the 
trial sites and the number of cases per site, in line with 
the CONSORT guidelines that require information on 
settings and locations where the data were collected. 
Second, when discussing the clinical development plan 
of a potentially life-saving drug, regulatory agencies 
should require an ethical clause that binds the marketing 
authorisation holders to register it in all MICs involved 
in the trials, to make it available at tiered prices based on 
the GNI of MICs, and to make such information publicly 
available. This will require the proactive involvement 
of local regulatory authorities. Third, physicians and 
patients from MICs, hopefully joined by their peers in 
affl  uent countries, should lobby for a fair price for the 
drugs tested in their countries.4 The implementation 
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of these and other measures will only succeed if 
grounded in a global collaborative eff ort and will foster 
the equitable distribution of burdens and benefi ts of 
participation in research. Such eff ort would contribute 
to fi lling the persisting gaps in access to life-saving 
therapies for non-communicable diseases.10
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